Morgan Stanley’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $64.7M | Buy |
1,011,143
+13,357
| +1% | +$693K | ﹤0.01% | 1976 |
|
|
2026
Q1 | $48M | Sell |
997,786
-362,258
| -27% | -$16M | ﹤0.01% | 2136 |
|
|
2025
Q4 | $56.1M | Sell |
1,360,044
-2,879
| -0.2% | -$115K | ﹤0.01% | 1975 |
|
|
2025
Q3 | $52.9M | Buy |
1,362,923
+296,644
| +28% | +$9.64M | ﹤0.01% | 1956 |
|
|
2025
Q2 | $29.5M | Sell |
1,066,279
-10,120
| -0.9% | -$258K | ﹤0.01% | 2428 |
|
|
2025
Q1 | $23.9M | Sell |
1,076,399
-411,348
| -28% | -$8.47M | ﹤0.01% | 2519 |
|
|
2024
Q4 | $29.4M | Buy |
1,487,747
+462,276
| +45% | +$10.6M | ﹤0.01% | 2358 |
|
|
2024
Q3 | $25.6M | Sell |
1,025,471
-960,015
| -48% | -$23.4M | ﹤0.01% | 2532 |
|
|
2024
Q2 | $37.1M | Buy |
1,985,486
+714,873
| +56% | +$13.4M | ﹤0.01% | 2033 |
|
|
2024
Q1 | $25.1M | Sell |
1,270,613
-1,920,345
| -60% | -$37.5M | ﹤0.01% | 2452 |
|
|
2023
Q4 | $56M | Buy |
3,190,958
+1,699,469
| +114% | +$27.9M | ﹤0.01% | 2316 |
|
|
2023
Q3 | $25.9M | Buy |
1,491,489
+182,746
| +14% | +$3.08M | ﹤0.01% | 2187 |
|
|
2023
Q2 | $18.4M | Sell |
1,308,743
-17,079
| -1% | -$229K | ﹤0.01% | 2559 |
|
|
2023
Q1 | $14.3M | Buy |
1,325,822
+720,278
| +119% | +$9.49M | ﹤0.01% | 2799 |
|
|
2022
Q4 | $9.07M | Buy |
605,544
+110,359
| +22% | +$1.61M | ﹤0.01% | 3184 |
|
|
2022
Q3 | $6.36M | Buy |
495,185
+46,290
| +10% | +$527K | ﹤0.01% | 3461 |
|
|
2022
Q2 | $4.35M | Buy |
448,895
+187,050
| +71% | +$1.75M | ﹤0.01% | 3884 |
|
|
2022
Q1 | $2.6M | Sell |
261,845
-94,919
| -27% | -$1.01M | ﹤0.01% | 4317 |
|
|
2021
Q4 | $4.2M | Buy |
356,764
+101,444
| +40% | +$1.25M | ﹤0.01% | 3896 |
|
|
2021
Q3 | $2.91M | Sell |
255,320
-128,614
| -33% | -$1.67M | ﹤0.01% | 4263 |
|
|
2021
Q2 | $5.35M | Buy |
383,934
+205,803
| +116% | +$3.13M | ﹤0.01% | 3712 |
|
|
2021
Q1 | $3.3M | Sell |
178,131
-41,529
| -19% | -$849K | ﹤0.01% | 3841 |
|
|
2020
Q4 | $3.88M | Buy |
219,660
+19,254
| +10% | +$338K | ﹤0.01% | 3534 |
|
|
2020
Q3 | $3.07M | Buy |
200,406
+162,930
| +435% | +$3.06M | ﹤0.01% | 3234 |
|
|
2020
Q2 | $955K | Buy |
37,476
+24,213
| +183% | +$506K | ﹤0.01% | 4213 |
|
|
2020
Q1 | $205K | Sell |
13,263
-122,489
| -90% | -$1.92M | ﹤0.01% | 4854 |
|
|
2019
Q4 | $1.5M | Buy |
135,752
+27,518
| +25% | +$239K | ﹤0.01% | 4249 |
|
|
2019
Q3 | $921K | Buy |
108,234
+48,136
| +80% | +$532K | ﹤0.01% | 4348 |
|
|
2019
Q2 | $814K | Buy |
60,098
+21,130
| +54% | +$328K | ﹤0.01% | 4337 |
|
|
2019
Q1 | $703K | Buy |
38,968
+14,808
| +61% | +$286K | ﹤0.01% | 4340 |
|
|
2018
Q4 | $679K | Buy |
24,160
+1,402
| +6% | +$29.3K | ﹤0.01% | 4593 |
|
|
2018
Q3 | $581K | Buy |
22,758
+1,037
| +5% | +$20.2K | ﹤0.01% | 4918 |
|
|
2018
Q2 | $376K | Buy |
+21,721
| New | +$393K | ﹤0.01% | 5269 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
Morgan Stanley's KNSA Position: Q2 2026 in Review
Morgan Stanley increased its Kiniksa Pharmaceuticals (KNSA) stake by 1.3% in Q2 2026, buying an estimated $693K and bringing the position to 1,011,143 shares worth $64.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1976.
Morgan Stanley first reported a position in KNSA in Q2 2018 and has held it in 33 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- Morgan Stanley held 1,011,143 shares of Kiniksa Pharmaceuticals worth $64.7M as of Q2 2026.
- Morgan Stanley bought 13,357 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $693K.
- Kiniksa Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #1976 holding.
- Morgan Stanley first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and has held it in 33 quarters since.
- 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.